Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • S. Karger AG  (4)
  • 2020-2024  (4)
  • 1
    In: Urologia Internationalis, S. Karger AG, Vol. 106, No. 11 ( 2022), p. 1168-1176
    Abstract: 〈 b 〉 〈 i 〉 Introduction: 〈 /i 〉 〈 /b 〉 Programmed death-1 ligand (PD-L1) has been often studied in different types of renal-cell carcinoma (RCC). For example, in clear-cell renal carcinoma it is well established that programmed death-1 receptor and PD-L1 are important prognostic markers. In contrast, the role of programmed death-2 ligand (PD-L2) as prognostic marker remains unclear. The aim of this study was to evaluate if PD-L2 expression could play a role as a prognostic marker for papillary RCC (pRCC). 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 The patients’ sample collection was a joint collaboration of the PANZAR consortium. Patients’ medical history and tumor specimens were collected from 〈 i 〉 n 〈 /i 〉 = 240 and 〈 i 〉 n 〈 /i 〉 = 128 patients with type 1 and 2 pRCC, respectively. Expression of PD-L2 was determined by immunohistochemistry. In total, PD-L2 staining was evaluable in 185 of 240 type 1 and 99 of 128 type 2 pRCC cases. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 PD-L2 staining was positive in 67 (36.2%) of type 1 and in 31 (31.3%) of type 2 pRCC specimens. The prevalence of PD-L2+ cells was significantly higher in high-grade type 1 tumors ( 〈 i 〉 p 〈 /i 〉 = 0.019) and in type 2 patients with metastasis ( 〈 i 〉 p 〈 /i 〉 = 0.002). Kaplan-Meier analysis disclosed significant differences in 5-year overall survival (OS) for patients with PD-L2− compared to PD-L2+ in pRCC type 1 of 88.4% compared to 73.6% ( 〈 i 〉 p 〈 /i 〉 = 0.039) and type 2 of 78.8% compared to 39.1% % ( 〈 i 〉 p 〈 /i 〉 & #x3c; 0.001). However, multivariate analysis did not identify the presence of PD-L2+ cells neither in type 1 nor type 2 pRCC as an independent predictor of poor OS. 〈 b 〉 〈 i 〉 Discussion/Conclusion: 〈 /i 〉 〈 /b 〉 PD-L2 expression did not qualify as an independent prognostic marker in pRCC. Future studies will have to determine whether anti-PD-L2-targeted treatment may play a role in pRCC and expression can potentially serve as a predictive marker for these therapeutic approaches.
    Type of Medium: Online Resource
    ISSN: 0042-1138 , 1423-0399
    RVK:
    Language: English
    Publisher: S. Karger AG
    Publication Date: 2022
    detail.hit.zdb_id: 1464417-4
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    In: Urologia Internationalis, S. Karger AG, Vol. 107, No. 7 ( 2023), p. 713-722
    Abstract: 〈 b 〉 〈 i 〉 Introduction: 〈 /i 〉 〈 /b 〉 Growth arrest-specific protein 6 (Gas 6) is a ligand that plays a role in proliferation and migration of cells. For several tumor entities, high levels of Gas 6 are associated with poorer survival. We examined the prognostic role of Gas 6 in renal cell carcinoma (RCC), especially in papillary RCC (pRCC), which is still unclear. 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 The patients’ sample collection is a joint collaboration of the PANZAR consortium. Patients’ medical history and tumor specimens were collected from 〈 i 〉 n 〈 /i 〉 = 240 and 〈 i 〉 n 〈 /i 〉 = 128 patients with type 1 and 2 pRCC, respectively. Expression of Gas 6 was determined by immunohistochemistry. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 In total, Gas 6 staining was evaluable in 180 of 240 type 1 and 110 of 128 type 2 pRCC cases. Kaplan-Meier analysis disclosed no significant difference in 5-year overall survival for all pRCC nor either subtype. Also, Gas+ and Gas– groups did not significantly differ in any tumor or patient characteristics. 〈 b 〉 〈 i 〉 Conclusion: 〈 /i 〉 〈 /b 〉 Gas 6 was not found to be an independent prognostic marker in pRCC. Future studies are warranted to determine if Gas 6 plays a role as prognostic marker or therapeutic target in pRCC.
    Type of Medium: Online Resource
    ISSN: 0042-1138 , 1423-0399
    RVK:
    Language: English
    Publisher: S. Karger AG
    Publication Date: 2023
    detail.hit.zdb_id: 1464417-4
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    In: Transfusion Medicine and Hemotherapy, S. Karger AG
    Abstract: 〈 b 〉 〈 i 〉 Introduction: 〈 /i 〉 〈 /b 〉 Patients undergoing revision total hip surgery (RTHS) have a high prevalence of mild and moderate preoperative anemia, associated with adverse outcomes. The aim of this study was to investigate the association of perioperative allogeneic blood transfusions (ABT) and postoperative complications in preoperatively mild compared to moderate anemic patients undergoing RTHS who did not receive a diagnostic anemia workup and treatment before surgery. 〈 b 〉 〈 i 〉 Methods: 〈 /i 〉 〈 /b 〉 We included 1,765 patients between 2007 and 2019 at a university hospital. Patients were categorized according to their severity of anemia using the WHO criteria of mild, moderate, and severe anemia in the first Hb level of the case. Patients were grouped as having received no ABT, 1–2 units of ABT, or more than 2 units of ABT. Need for intraoperative ABT was assessed in accordance with institutional standards. Primary endpoint was the compound incidence of postoperative complications. Secondary outcomes included major/minor complications and length of hospital and ICU stay. 〈 b 〉 〈 i 〉 Results: 〈 /i 〉 〈 /b 〉 Of the 1,765 patients, 31.0% were anemic of any cause before surgery. Transfusion rates were 81% in anemic patients and 41.2% in nonanemic patients. The adjusted risks for compound postoperative complication were significantly higher in patients with moderate anemia (OR 4.88, 95% CI: 1.54–13.15, 〈 i 〉 p 〈 /i 〉 = 0.003) but not for patients with mild anemia (OR 1.93, 95% CI: 0.85–3.94, 〈 i 〉 p 〈 /i 〉 & lt; 0.090). Perioperative ABT was associated with significantly higher risks for complications in nonanemic patients and showed an increased risk for complications in all anemic patients. In RTHS, perioperative ABT as a treatment for moderate preoperative anemia of any cause was associated with a negative compound effect on postoperative complications, compared to anemia or ABT alone. 〈 b 〉 〈 i 〉 Discussion: 〈 /i 〉 〈 /b 〉 ABT is associated with adverse outcomes of patients with moderate preoperative anemia before RTHS. For this reason, medical treatment of moderate preoperative anemia may be considered.
    Type of Medium: Online Resource
    ISSN: 1660-3796 , 1660-3818
    Language: English
    Publisher: S. Karger AG
    Publication Date: 2023
    detail.hit.zdb_id: 2100533-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    Online Resource
    Online Resource
    S. Karger AG ; 2023
    In:  Transfusion Medicine and Hemotherapy Vol. 50, No. 2 ( 2023), p. 107-115
    In: Transfusion Medicine and Hemotherapy, S. Karger AG, Vol. 50, No. 2 ( 2023), p. 107-115
    Abstract: 〈 b 〉 〈 i 〉 Background: 〈 /i 〉 〈 /b 〉 Different preparations for therapeutic plasma are available on the market. The German hemotherapy guideline has been completely updated in 2020 and, for this purpose, has reviewed the evidence for the most frequent clinical indications for the use of therapeutic plasma in adult patients. 〈 b 〉 〈 i 〉 Summary: 〈 /i 〉 〈 /b 〉 The German hemotherapy guideline has reviewed the evidence for the following indications for the use of therapeutic plasma in the adult patient: massive transfusion and bleeding, severe chronic liver disease, disseminated intravascular coagulation, plasma exchange for TTP, and the rare hereditary FV and FXI deficiencies. The updated recommendations for each indication are discussed on the background of existing guidelines and new evidence. For most indications, the quality of evidence is low due to missing prospective randomized trials or rare diseases. However, due to the “balanced” content of coagulation factors and inhibitors therapeutic plasma remains an important pharmacological treatment option in clinical situations with an already activated coagulation system. Unfortunately, the “physiological” content of coagulation factors and inhibitors limits the efficacy in clinical scenarios with high blood losses. 〈 b 〉 〈 i 〉 Key Messages: 〈 /i 〉 〈 /b 〉 The evidence for the use of therapeutic plasma for the replacement of coagulation factors due to massive bleeding is poor. Coagulation factor concentrates seem to be more appropriate for this indication, although the quality of evidence is also low. However, for diseases with an activated coagulation or endothelial system (e.g., disseminated intravascular coagulation, TTP) the balanced replacement of coagulation factors, inhibitors, and proteases may be of advantage.
    Type of Medium: Online Resource
    ISSN: 1660-3796 , 1660-3818
    Language: English
    Publisher: S. Karger AG
    Publication Date: 2023
    detail.hit.zdb_id: 2100533-3
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages